Sign Up
OverviewAPI
Ipsen, a global biopharmaceutical company, has presented its sales performance for the first nine months of 2023 and the third quarter of 2023. The company has received regulatory approval for Sohonos, positive results in the CONTACT-02 trial for Cabometyx, and received a negative opinion from the European Medicines Agency regarding the orphan designation for Bylvay in Alagille syndrome. Ipsen has also appointed Christelle Huguet as Executive Vice President, Head of Research and Development, succeeding Howard Mayer.

Ask a question